130.40
price down icon2.42%   -3.24
 
loading
Gilead Sciences Inc stock is traded at $130.40, with a volume of 5.95M. It is down -2.42% in the last 24 hours and down -5.58% over the past month. Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$133.64
Open:
$131.54
24h Volume:
5.95M
Relative Volume:
0.88
Market Cap:
$161.85B
Revenue:
$29.45B
Net Income/Loss:
$8.51B
P/E Ratio:
19.23
EPS:
6.7823
Net Cash Flow:
$9.46B
1W Performance:
-5.26%
1M Performance:
-5.58%
6M Performance:
+7.82%
1Y Performance:
+22.85%
1-Day Range:
Value
$129.28
$132.32
1-Week Range:
Value
$129.28
$138.54
52-Week Range:
Value
$93.37
$157.29

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Name
Gilead Sciences Inc
Name
Phone
(650) 574-3000
Name
Address
333 LAKESIDE DR, FOSTER CITY, CA
Name
Employee
17,000
Name
Twitter
@GileadSciences
Name
Next Earnings Date
2026-05-07
Name
Latest SEC Filings
Name
GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, AZN, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
GILD icon
GILD
Gilead Sciences Inc
130.40 161.85B 29.45B 8.51B 9.46B 6.7823
LLY icon
LLY
Lilly Eli Co
883.96 789.69B 65.18B 20.64B 5.96B 22.59
JNJ icon
JNJ
Johnson Johnson
227.50 547.64B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
198.71 351.47B 61.16B 4.19B 17.82B 2.3614
AZN icon
AZN
Astrazeneca Plc
189.75 294.27B 58.80B 10.24B 8.98B 3.2788
NVS icon
NVS
Novartis Ag Adr
145.47 277.58B 54.72B 14.02B 15.32B 7.1855

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-10-26 Initiated Jefferies Buy
Feb-20-26 Initiated Barclays Equal Weight
Feb-11-26 Reiterated Needham Buy
Jan-07-26 Resumed UBS Buy
Nov-24-25 Resumed Truist Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Aug-19-25 Upgrade Daiwa Securities Neutral → Outperform
Aug-08-25 Upgrade Truist Hold → Buy
Jul-25-25 Upgrade Needham Hold → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Mar-04-25 Reiterated Oppenheimer Outperform
Feb-18-25 Upgrade Deutsche Bank Hold → Buy
Feb-13-25 Upgrade DZ Bank Hold → Buy
Jan-10-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Buy
Nov-08-24 Downgrade Maxim Group Buy → Hold
Oct-21-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-17-24 Initiated Bernstein Outperform
Oct-07-24 Upgrade Wells Fargo Equal Weight → Overweight
Jul-08-24 Upgrade Raymond James Mkt Perform → Outperform
May-01-24 Reiterated Maxim Group Buy
Apr-24-24 Upgrade HSBC Securities Reduce → Hold
Feb-22-24 Downgrade Truist Buy → Hold
Nov-09-23 Initiated Deutsche Bank Hold
Sep-08-23 Upgrade BofA Securities Neutral → Buy
Sep-06-23 Initiated HSBC Securities Reduce
Jul-24-23 Reiterated Barclays Equal Weight
May-16-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-28-23 Resumed Piper Sandler Overweight
Jan-03-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-13-22 Resumed BofA Securities Neutral
Dec-09-22 Downgrade DZ Bank Buy → Hold
Oct-31-22 Upgrade Barclays Underweight → Equal Weight
Oct-28-22 Reiterated BMO Capital Markets Market Perform
Oct-28-22 Reiterated Cowen Outperform
Oct-28-22 Reiterated JP Morgan Overweight
Oct-28-22 Reiterated Jefferies Buy
Oct-28-22 Upgrade Piper Sandler Neutral → Overweight
Oct-28-22 Reiterated RBC Capital Mkts Outperform
Oct-28-22 Upgrade Truist Hold → Buy
Oct-28-22 Reiterated Wells Fargo Equal Weight
Oct-04-22 Upgrade JP Morgan Neutral → Overweight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
May-23-22 Initiated SVB Leerink Mkt Perform
Feb-28-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-02-22 Reiterated BMO Capital Markets Outperform
Feb-02-22 Reiterated BofA Securities Neutral
Feb-02-22 Reiterated RBC Capital Mkts Outperform
Feb-02-22 Reiterated Truist Hold
Feb-02-22 Reiterated Wells Fargo Equal Weight
Jan-28-22 Upgrade Argus Hold → Buy
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Upgrade BMO Capital Markets Market Perform → Outperform
Nov-19-21 Resumed Piper Sandler Neutral
Oct-20-21 Resumed Cowen Outperform
Jul-30-21 Reiterated BMO Capital Markets Market Perform
Jul-30-21 Reiterated RBC Capital Mkts Outperform
Apr-01-21 Upgrade Bernstein Mkt Perform → Outperform
Mar-30-21 Upgrade Redburn Neutral → Buy
Jan-19-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Nov-03-20 Resumed Morgan Stanley Equal-Weight
Oct-28-20 Initiated UBS Neutral
Sep-30-20 Resumed Jefferies Buy
Sep-15-20 Upgrade Maxim Group Hold → Buy
Jul-31-20 Reiterated Credit Suisse Neutral
Jul-31-20 Reiterated Morgan Stanley Equal-Weight
Jul-31-20 Reiterated Piper Sandler Overweight
Jul-31-20 Reiterated RBC Capital Mkts Outperform
Jul-31-20 Reiterated SunTrust Hold
Jul-31-20 Reiterated Wells Fargo Equal Weight
Jul-20-20 Upgrade Credit Suisse Underperform → Neutral
Jun-03-20 Upgrade SVB Leerink Mkt Perform → Outperform
May-26-20 Upgrade SunTrust Sell → Hold
May-01-20 Downgrade JP Morgan Overweight → Neutral
May-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-01-20 Downgrade SunTrust Hold → Sell
Apr-27-20 Downgrade UBS Buy → Neutral
Apr-20-20 Downgrade BMO Capital Markets Outperform → Market Perform
Apr-20-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Downgrade CFRA Hold → Sell
View All

Gilead Sciences Inc Stock (GILD) Latest News

pulisher
08:24 AM

Vanguard Group Inc. Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

08:24 AM
pulisher
04:36 AM

Concurrent Investment Advisors LLC Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat

04:36 AM
pulisher
03:18 AM

Axecap Investments LLC Has $3.43 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

03:18 AM
pulisher
03:12 AM

AEGON ASSET MANAGEMENT UK Plc Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

03:12 AM
pulisher
Apr 25, 2026

Impax Asset Management Group plc Acquires 19,894 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 25, 2026
pulisher
Apr 25, 2026

Gilead Sciences, Inc. $GILD Shares Sold by Polaris Capital Management LLC - MarketBeat

Apr 25, 2026
pulisher
Apr 25, 2026

Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability - ChartMill

Apr 25, 2026
pulisher
Apr 25, 2026

Calamos Advisors LLC Sells 9,121 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 25, 2026
pulisher
Apr 24, 2026

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance Australia

Apr 24, 2026
pulisher
Apr 24, 2026

Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch

Apr 24, 2026
pulisher
Apr 24, 2026

Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD - Yahoo Finance

Apr 24, 2026
pulisher
Apr 24, 2026

NBC Securities Inc. Acquires 10,296 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 24, 2026
pulisher
Apr 24, 2026

Gilead Sciences, Inc. $GILD is Kerusso Capital Management LLC's 6th Largest Position - MarketBeat

Apr 24, 2026
pulisher
Apr 24, 2026

Teacher Retirement System of Texas Sells 33,061 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 24, 2026
pulisher
Apr 24, 2026

Gilead Sciences, Inc. $GILD Stake Boosted by China Universal Asset Management Co. Ltd. - MarketBeat

Apr 24, 2026
pulisher
Apr 24, 2026

Gilead Sciences, Inc. $GILD Shares Sold by Arizona State Retirement System - MarketBeat

Apr 24, 2026
pulisher
Apr 24, 2026

Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN

Apr 24, 2026
pulisher
Apr 23, 2026

Transforming What’s Next, Now: Gilead’s 2025 Responsible Business and Impact Report - Gilead Sciences

Apr 23, 2026
pulisher
Apr 23, 2026

Gilead Sciences (GILD) Ends Losing Streak with 0.56% Gain - GuruFocus

Apr 23, 2026
pulisher
Apr 23, 2026

Gilead Sciences nears $2B deal for Ouro MedicinesFT - MSN

Apr 23, 2026
pulisher
Apr 23, 2026

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy - Benzinga

Apr 23, 2026
pulisher
Apr 23, 2026

Milestone Asset Management LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Apr 23, 2026
pulisher
Apr 23, 2026

Gilead Sciences: Core HIV and Liver Franchises Drive EPS Upside and Support Buy Rating Despite Cell Therapy Headwinds - TipRanks

Apr 23, 2026
pulisher
Apr 23, 2026

GILD (Gilead Sciences Inc.) reports narrow Q4 2025 earnings beat and mild revenue growth, shares dip slightly.Mature Phase - Xã Thanh Hà

Apr 23, 2026
pulisher
Apr 23, 2026

Gilead Sciences, Inc. $GILD Holdings Decreased by Ruffer LLP - MarketBeat

Apr 23, 2026
pulisher
Apr 23, 2026

Caprock Group LLC Buys 12,895 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 23, 2026
pulisher
Apr 23, 2026

B. Metzler seel. Sohn & Co. AG Acquires 17,584 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Apr 23, 2026
pulisher
Apr 22, 2026

Gilead Sciences Inc. (GILD) Announces Q1 2026 Earnings Release Date, Signaling Near-Term Upside CatalystSurprise Factor - Xã Thanh Hà

Apr 22, 2026
pulisher
Apr 22, 2026

FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral - MedCity News

Apr 22, 2026
pulisher
Apr 22, 2026

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Business Wire

Apr 22, 2026
pulisher
Apr 22, 2026

Gilead Sciences stock price forecast: limited upside as GILD trades near support after weekly decline - Traders Union

Apr 22, 2026
pulisher
Apr 22, 2026

Gilead set to report as Yeztugo launch, M&A strategy face test - Investing.com

Apr 22, 2026
pulisher
Apr 22, 2026

Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat

Apr 22, 2026
pulisher
Apr 22, 2026

Merck steps up as ‘meaningful competitor’ to Gilead with HIV pill approval - BioSpace

Apr 22, 2026
pulisher
Apr 22, 2026

Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st

Apr 22, 2026
pulisher
Apr 21, 2026

Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 21, 2026
pulisher
Apr 21, 2026

Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - Yahoo Finance

Apr 21, 2026
pulisher
Apr 21, 2026

Release of 2025 impact report weighs on Gilead Sciences stock amid oversold momentum signals - Traders Union

Apr 21, 2026
pulisher
Apr 21, 2026

Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026? - TIKR.com

Apr 21, 2026
pulisher
Apr 21, 2026

7,568 Shares in Gilead Sciences, Inc. $GILD Acquired by Ticino Wealth - MarketBeat

Apr 21, 2026
pulisher
Apr 21, 2026

Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls - BioSpace

Apr 21, 2026
pulisher
Apr 21, 2026

Gilead Sciences : Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions - marketscreener.com

Apr 21, 2026
pulisher
Apr 21, 2026

Arcus pulls another TIGIT trial as Gilead steps back - The Pharma Letter

Apr 21, 2026
pulisher
Apr 21, 2026

Zacks Research Predicts Lower Earnings for Gilead Sciences - MarketBeat

Apr 21, 2026
pulisher
Apr 21, 2026

Gilead Sciences, Inc. (GILD) Stock Analysis: A Healthcare Giant with a 15% Upside Potential - DirectorsTalk Interviews

Apr 21, 2026
pulisher
Apr 21, 2026

GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill

Apr 21, 2026
pulisher
Apr 20, 2026

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance

Apr 20, 2026
pulisher
Apr 20, 2026

Lobbying Update: $3,190,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative

Apr 20, 2026
pulisher
Apr 20, 2026

Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 EarningsBut Won't (NASDAQ:GILD) - Seeking Alpha

Apr 20, 2026
pulisher
Apr 20, 2026

Leerink cuts Arcus Biosciences stock price target on Gilead collaboration end - Investing.com Canada

Apr 20, 2026
pulisher
Apr 20, 2026

Gilead Sciences stock edges lower as company discusses expanding oncology reach at AACR26 - Traders Union

Apr 20, 2026

Gilead Sciences Inc Stock (GILD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Gilead Sciences Inc Stock (GILD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mercier Johanna
Chief Comm & Corp Aff Officer
Apr 15 '26
Sale
140.96
3,000
422,880
128,779
PFE PFE
$27.00
price up icon 1.24%
NVO NVO
$41.17
price up icon 6.88%
$344.55
price down icon 1.17%
MRK MRK
$111.90
price down icon 2.37%
NVS NVS
$145.47
price down icon 1.36%
Cap:     |  Volume (24h):